EIC Fund Investment Guidelines 2026: The Full Rulebook Behind Your Equity Component

On 27 August 2026, the European Innovation Council and SMEs Executive Agency published an updated set of investment guidelines for the Horizon Europe compartment of the EIC Fund. The document is short by regulatory standards, at eighteen pages, but it is the single most consequential text an EIC Accelerator company will read after the Work Programme, because it governs what happens to the equity component once the grant is signed.

Most applicants treat EIC funding as one decision. The guidelines make clear that it is two. The grant follows Horizon Europe rules and is settled through the grant agreement. The investment component follows a separate investment process, run by a different set of actors, under a separate legal framework, with its own grounds for refusal. A company can hold a signed grant agreement and still never receive a euro of equity.

This article works through the document clause by clause and translates it into what it means for a company sitting between a funding recommendation and a wire transfer.

What Changed in the 2026 Version

The update was framed by the Agency as an alignment exercise rather than a redesign. Four areas were brought into line with the current EIC Work Programme, and two substantive additions were made.

The text applies to companies selected under the EIC Accelerator (blended finance and equity-only) and under the EIC STEP Scaleup. Guidelines for the Scaleup Europe Fund will be issued separately once that compartment is established in August 2026.

For context on scale: the EIC Fund has been operating since June 2020, has invested in more than 360 deep tech companies across Europe, and reports leveraging over €3.5 of additional investment for every €1 it invests directly. That leverage figure is not a marketing line. It is the operating target embedded in the guidelines, and it explains most of the conditions described below.

Who Actually Decides

The guidelines distribute authority across four parties, and applicants routinely address the wrong one.

• The EU Commission makes the award decision. Maximum investment amounts per company must be authorised ex ante through that decision, and any investment safeguards attached to a specific case are identified there.
• The External AIFM is the alternative investment fund manager. It takes the investment decision, negotiates and signs the documentation, contracts with and finances the company, and holds full discretion over any exit.
• The Adviser performs market consultation, recommends, categorises transactions, negotiates terms with co-investors and supplies investment officers who sit on boards as proxies or observers.
• EISMEA ran the evaluation and retains operational coordination of tranching for as long as the EIC Accelerator support is in force.

The practical consequence is that the evaluators who scored your proposal do not decide your investment. The guidelines state directly that the investment amount decided by the External AIFM may be lower or higher than the amount proposed by the independent expert evaluators during the EISMEA evaluation, subject to the terms of the Commission award decision.

Who Is Eligible

Eligible applicants are for-profit highly innovative SMEs, including start-ups and early-stage companies, and small mid-caps, from any sector, typically with a strong intellectual property component. A small mid-cap is defined by footnote as an enterprise with up to 499 employees that is not already a micro, small or medium-sized enterprise under the Commission SME Recommendation.

Companies must be established and operating in an EU Member State or a country associated to Horizon Europe Pillar III equity component. There is one important structural flexibility: the External AIFM may decide to invest not in the entity that submitted the proposal but in its holding or parent company established in an eligible territory. This requires a recommendation from the investment advisor containing a justification of the need in the specific case, plus confirmation that the holding or parent itself meets all eligibility criteria, in particular SME status and non-bankability.

That clause matters for any group with a foreign topco. It is not an invitation to restructure freely. The parent has to independently satisfy the same tests the operating company did.

Israeli entities face a specific condition. To comply with Commission Notice 2013/C 205/05, only entities established within Israel's pre-1967 borders and not operating in the Golan Heights, the Gaza Strip or the West Bank including East Jerusalem are eligible, and every agreement with an Israeli recipient must include a standard compliance article by default.

Ticket Size, Stake and Instrument

The headline parameters are compact enough to state in one paragraph, and they are the numbers most applicants get wrong when modelling their round.

Two instrument details are easy to miss. First, the Fund can make secondary share purchases, confirmed explicitly in the text. This is used where EU interests need protecting, for example when exercising pre-emption rights to buy out existing investors in order to secure European ownership, or when restructuring a cap table to align with the conditions of an investment round. Decisions are case by case on the basis of the Commission award decision.

Second, and directly relevant to any shareholder agreement you are currently negotiating, the Fund will strive to hold a right of first refusal over the shares of any exiting shareholder on a pro rata basis, subject to local company law. It states that it could exercise that right where shares would otherwise be sold to a company established in, or an individual of, a non-eligible country, on economic security grounds.

The Four Buckets

The operational heart of the guidelines is a categorisation exercise. After an initial assessment involving some due diligence and KYC compliance checks, plus a market consultation led by the Adviser, every transaction is sorted into one of four buckets. The classification is explicitly not static: cases move between buckets as due diligence findings emerge, as co-investor interest is triggered by the de-risking effect of the EIC award, or as milestones are reached later in the project.

Knowing your likely bucket before due diligence starts is the most useful piece of preparation available. A company that walks into the process with a term sheet from a credible fund is in a structurally different conversation from a company that arrives with a grant award and nothing else.

Bucket 0: The Disqualifiers

The guidelines are unusually candid about the relationship between evaluation and due diligence. The stated purpose of due diligence is not to re-evaluate the proposal or question the rationale of the award, but it is by definition a more in-depth examination, and findings may lead to questioning the legality or the rationale of the operation.

Negative issues explicitly include fraud, money laundering, tax avoidance, non-compliance including sanctions, exclusion criteria, misrepresentation, refusal or failure to submit requested information, insufficient information for the Investment Committee to reach an informed decision, manifest error at evaluation, substantial negative changes of circumstances (Material Adverse Changes), reputational risk for the EU, and other findings affecting EU financial interests. The document then gives worked examples, and this list deserves reading as a checklist rather than as legal boilerplate.

• The innovation does not show the solid, long-lasting competitive advantage and impact on the basis of which the operation was selected.
• The team has changed since evaluation and no longer gathers the strong skills, capabilities and motivation needed to get the company off the ground and scale up.
• Other Material Adverse Changes since the EISMEA assessment, including major changes in management, changes in control, use of bad leaver provisions, serious litigation including among shareholders, or loss of major suppliers, clients or partners on which the company is heavily dependent.
• The cap table evidences strong misalignment of existing shareholder interests, or a lack of sufficient incentive for founders and the key team.
• The applicant refuses or is unable to provide information the Investment Committee considers necessary, including information on an existing investor or shareholder and its ultimate beneficial owners, in relation to possible reputational risk for the EU.
• An existing shareholder or its ultimate beneficial owner falls under an exclusion case in the EU Financial Regulation.
• Financial data and documentation submitted at proposal stage contradicts the applicant's books.
• Alleged intellectual property is not directly owned by or accessible to the applicant, or is the subject of litigation.
• An existing shareholder or its ultimate beneficial owner is established in or is a national of a non-eligible country for the purposes of the award decision, or, for a legal entity, is effectively controlled by companies or nationals from such countries.

Three of these are worth calling out because they are the ones companies create for themselves. Financial statements that contradict the proposal is a self-inflicted wound: the numbers in your application will be checked against your books. IP that is licensed rather than owned, or IP under dispute, is a recurring failure point for university spinouts that never completed the assignment. And a cap table with founders diluted to the point of demotivation is read as an investment risk, not as a private matter.

Note also that KYC extends beyond the company. Checks on the selected applicant are extended to the shareholders and their ultimate beneficial owners, and are repeated before each subsequent tranche, top-up and follow-on investment. An existing investor can therefore become the reason an investment stops, at a point long after signature.

Bucket 1: The Convertible Loan Path

Bucket 1 covers companies with shortcomings that can be remedied through the Fund's support: very early stage technology, an over-long time to market, a market that is small relative to the investment needed, or low readiness to absorb equity in terms of team or cap table.

Three sub-cases are envisaged, and the guidelines note they are neither exhaustive nor mutually exclusive: cases where the Commission conditions the award on acquiring a blocking minority, cases where the innovation has high potential impact by addressing a societal need or EU priority, and all other cases.

Where the Fund invests in tranches, it takes a position on the entire amount considered for funding, then releases it against milestones. The indicative first-tranche terms are set out in unusual detail, and these are the numbers to model.

Read the second tranche condition carefully, because it is the clause that strands companies. The matching requirement covers the totality of the Fund's investment, including the convertible loan already provided. A company that took €5 million as a first tranche and needs €5 million more must assemble €10 million of private money, not €5 million. The Fund may additionally require that those co-investors are Qualified Investors, and may set a minimum round size based on the financing needs it estimates are required to reach the market and scale up.

Where the loan reaches maturity without a qualified round large enough to convert the full amount, the guidelines commit only to the External AIFM engaging with founders and other investors on a way forward. There is no automatic remedy. The Adviser may advise on co-investment opportunities for the subsequent round.

Governance follows the money. Where the Fund operates as a major investor, defined in the second sub-case as 10% ownership or more, it will pursue a board member seat, and in the blocking-minority sub-case it will ensure one. External mentoring will be sought, and in some Bucket 1 cases mandatory mentoring may be required as a condition of the investment.

Buckets 2 and 3: When the Market Is Already There

Bucket 2 is the scenario the programme is designed to produce. The Fund seeks that its equity investment is at least matched by the interested investors, so that they cover at least 50% of the round, with an objective of 1:3 leverage across the full EIC investment cycle. In this configuration the Fund may rely on the financial, commercial and technology due diligence performed by Qualified Investors and should seek alignment to their terms, which is the fastest route through the process available to any applicant.

Bucket 2 also introduces the top-up mechanism: the Fund may reserve part of the initially awarded investment as an additional investment of the unused authorised amount, for a later step. And where the award was conditioned on a blocking minority, the Fund may substitute a shareholder agreement providing similar guarantees for EU interests instead of taking the stake directly.

Bucket 3 covers companies where investors are ready to provide the entire investment. The Fund may still co-invest, but only for a specific reason: to secure a blocking minority protecting EU interests as identified in the award decision. Otherwise it may reserve the authorised amount as a possible top-up for a later step. A well-funded company should not assume its EIC equity simply converts into cash on demand.

The Co-Investment Arithmetic

For direct equity, excluding quasi-equity instruments, the Fund will systematically seek co-investment and syndication with other investors on at least a 1:1 matching basis, while seeking a 1:3 leverage effect across the investment horizon. In these cases the Fund should only invest if market support, including from InvestEU, cannot be secured.

That last condition is the non-bankability test restated as an investment rule rather than an eligibility criterion. The EIC Accelerator is positioned as complementary to InvestEU, which is investor and financial intermediary driven, and is designed to act as initial or first risk-taker where needed. If your company can raise from the market on reasonable terms, the guidelines point away from EIC equity, not towards it.

Applicants are entitled to and explicitly encouraged to look for co-investors themselves, and the External AIFM will connect potential recipients to the EIC investor community to leverage co-investment opportunities, subject to non-disclosure obligations. Where the company and the Fund both consent to a proposed co-investment, due diligence and negotiations may be performed jointly with the co-investor, under the control of the External AIFM and the Adviser.

The stated investor universe is broad: business angels, venture capital funds, impact investment funds, family offices, venture debt funds, national promotional banks and institutions, and corporate venture arms. The guidelines are also candid that money is not the only point, since Qualified Investors bring knowledge, expertise, teams and networks that help reinforce team and business strategy.

There is a balancing principle attached. Terms should keep founders and employees sufficiently incentivised while applying market terms to attract private investors, and should remain investor-friendly. The Fund is explicitly conscious of not creating market distortion while filling a financing gap for high-risk targets.

Due Diligence: What Gets Examined

Compliance checks run first: identification of shareholders and ultimate beneficial owners established in or nationals of non-eligible countries, anti-money laundering, anti-terrorism financing, tax avoidance, non-cooperative jurisdictions and sanctions. A KYC self-certification may be collected together with the full Accelerator proposal, but it is not considered during evaluation, only by the External AIFM once the proposal is retained.

Financial and commercial due diligence then focuses on seven areas, which map almost exactly onto a conventional venture diligence scope:

• Governance and quality of the company's management
• Capital structure and financial planning
• Business strategy
• Competition
• Market assessment
• Value creation
• Legal form and jurisdictions

Technology due diligence is systematic as part of the initial assessment, and the Investment Committee may require additional technology due diligence case by case. The rationale given is that technology assessed before the award decision may need to be complemented by a deeper investor-angle review, or to investigate concerns raised about misrepresentation or manifest error regarding technology and market prospects. The Advisory Committee, the Adviser or the Investment Committee may call in Commission staff with relevant technology experience, EIC Programme Managers, or technology expertise from national innovation agencies.

For an applicant, that means the technical claims made in Step 2 are not retired at the interview. They can be re-examined by different people, with an investor's questions rather than an evaluator's scoring grid, months later.

Milestones, Suspension and the Grant Link

Milestones are defined as meaningful achievements in the development of the innovative project, reflecting maturity stages and TRLs achieved, including co-investment leveraged. Support finances company activities as long as relevant milestones are achieved.

The consequences are stated plainly. Support shall be suspended, amended or, if duly justified, terminated if measurable milestones are not reached, and may be terminated where expected market deployment, especially in the EU, cannot realistically be met.

There is also a cross-default between the two components that companies should understand before signing anything. A material breach of the EIC Accelerator contract related to the grant component shall prevent the Fund from further investing and may lead to early exit, and the relationship runs in both directions.

Protecting EU Interests

Where the Commission identifies a need for investment safeguards in a specific award decision, the compartment will take at least one of a defined set of measures: a secondary share purchase, acquiring a blocking stake, investing even where potential investors show immediate interest in providing the full investment, disposing of the compartment's interest via a secondary sale, follow-on investments, or securing European ownership of the intellectual property and of the company.

Alongside that sits a general commitment: when negotiating, implementing and monitoring investments, the Fund will ensure that supported companies keep most of their value, including their intellectual property, in the EU or Associated Countries, to contribute to economic growth and job creation.

On intellectual property specifically, grant-only support and the grant component of blended finance remain subject to the Horizon Europe IP rules, in particular Articles 38 to 41 of the Horizon Europe Regulation. Within national law, companies and co-investors are given maximum autonomy over IP management, in the interest of deploying the innovation, attracting further investment and enabling an effective exit. But where EU interests need protecting, including when the Fund takes a blocking minority, it will seek to secure that IP remains within the EU and Associated Countries and with the company wherever that makes sense for its development. The same principle applies at exit.

If your commercialisation plan involves assigning core IP to a US entity after the round closes, that plan and these guidelines are in direct tension, and the tension should be resolved before signature rather than after.

What Happens If Something Goes Wrong

Eligibility, including possible fraud, misrepresentation and non-compliance with sanctions, is checked at each tranche disbursement by both the External AIFM and EISMEA in a coordinated manner. Ineligibility may lead to termination of the investment agreement, at which point further investment stops and the Fund exits. Where fraud is detected, the Commission may terminate and even cancel the Accelerator support and recover all amounts paid, in addition to the sanctions provided for in the EU Financial Regulation.

The investment documentation contains protection clauses for material breach, fraud, non-compliance including sanctions, and for the case where the company falls under the control of investors from non-eligible countries. In such cases the recipient may have to fully reimburse or cash settle the support received. For the equity component the remedies include disposal of the Fund's interest via a secondary sale, including the right to sell its shares for one euro to remaining shareholders established in or nationals of an EU Member State or associated country, provided that legal entities among them are not controlled by companies or nationals from non-eligible countries.

The guidelines are equally honest about the limits of these remedies. Given the equity and quasi-equity nature of the investments, it is recognised that the Fund will typically have no or limited remedies, or exit and repayment possibilities, if a company breaches eligibility criteria or other terms. That candour cuts both ways: it explains why the pre-investment scrutiny is as heavy as it is.

Monitoring, Board Seats and Publicity

The External AIFM manages individual investments, including monitoring and acting on milestone funding, conversions, follow-on financing, write-downs, restructurings and exits. Qualified representatives or independent experts may be appointed to sit on company boards as voting members, discussed case by case during due diligence and recorded in the signed documents.

Voting itself is tightly constrained. Investment officers of the Adviser are appointed as proxies, and they exercise the Fund's voting rights strictly in accordance with prior written voting instructions recorded in a proxy appointment. The proxy does not authorise any discretion on any matter of other business, or on any resolution that does not match the agenda resolutions set out in the instructions. Investment officers may separately be nominated to non-voting observer seats.

For founders, the practical reading is that the Fund's representative at a shareholders' meeting cannot improvise. Anything not on the circulated agenda cannot be voted on by the proxy, which makes agenda drafting and advance notice materially more important than with a typical VC shareholder.

Two publicity obligations attach to every investment agreement. The company must acknowledge that the Fund or the Adviser may communicate information about it regardless of the amount received, including name and locality, the amount invested and the nature of the business and the investment. And the company must provide a written acknowledgment, in substantially prescribed terms, that the investment was provided by the EIC Fund set up under the European Innovation Council.

Follow-On Investments: The Definition That Matters

This is the section most likely to be misread, because the guidelines use "follow-on" in a narrower sense than the market does.

A footnote states that follow-on investments include only investments going beyond the maximum amount set out in the Commission award decision. Investments in different steps, where the Fund invests one part of the equity amount and later invests another part during a subsequent funding round, are not follow-on investments, as long as the total stays within the awarded amount.

The distinction has consequences. A staged second tranche within your awarded envelope is an ordinary implementation step. A genuine follow-on requires an ex ante amending award decision by the Commission, and is available only to companies that remain eligible for EIC Accelerator support, under the conditions of the applicable Work Programme.

Further conditions apply to genuine follow-ons. They will not crowd out smaller investments. They must satisfy the Horizon Europe requirements for EIC blended finance, meaning the recipient is still an SME or, in exceptional cases, a small mid-cap; continued EIC support is necessary; support through InvestEU is not yet possible; and state aid consistency is ensured. They also require that budget remains available to the Commission in the year in question, subject to a valid financing decision.

Separately, where the Commission awards an additional investment to a Horizon 2020 EIC Pilot operation following a call, that operation is transferred under this compartment.

Duration and Exit

The Fund describes itself as investing patient capital, with a long average perspective on return of seven to ten years and a maximum of generally fifteen years. Return levels are assessed case by case, and the stated main objective is impact investment rather than maximising return, while a positive return is always planned at the time of investment in line with general market practice.

Exit strategy is set case by case in close cooperation with co-investors, given the specifics of each business plan, founding team, industry, expected holding period and development against the initial milestones. Exit routes may include IPOs, management buy-outs, secondary sales or liquidations. Any divestment decision is made by the External AIFM in its full discretion.

The exit logic is worth understanding because it differs from a standard VC clock:

• The Fund generally follows the lead investor. The exit process should be driven by co-investors, in particular a lead investor, and the Fund should generally divest alongside them, unless extension is justified, and always subject to a new investor entering as a co-investor.
• It may also exit earlier than the lead. Where a co-investor clearly intends to stay for a very long time and EIC support is no longer needed, the Fund should exit before them, in order to make EIC funding available for new companies.
• Market access triggers divestment. Divestment should take place when the company can be financed from market sources including InvestEU, because EIC support is then no longer needed.
• Failure has its own path. Less favourable scenarios, including exiting below the initial investment amount, are to be considered where customary exit conditions are not met or the company has failed to develop successfully. Failure to find co-investors is itself a reason to exit. In insolvency the Fund may not control the process at all, and does not rule out exit via redemption or sale to a third party at a symbolic price.

Preparation for exit is expected to start early, guided by pari passu terms and regular interaction with other investors. Three specific preparations are named: an initial setup aligning investor interests, the Fund's public service mission and management interests, generally ensured through a solid employee stock ownership plan; definition of the metrics deemed key to a successful exit in the sector concerned, with a plan to optimise them; and, except for an IPO, early identification of a pool of potential acquirers, then direct engagement, then initiation of an exclusive process or an auction.

The ESOP point is a concrete instruction hiding in a procedural paragraph. If your company has no meaningful employee equity plan, the guidelines treat that as a gap in exit readiness, and the Bucket 0 language about insufficient founder and key team incentives treats it as an investment risk.

Excluded Activities

The Fund will not invest in any person conducting an excluded activity. This sits on top of the general exclusions in the EU Financial Regulation, the restrictive measures adopted under Article 215 TFEU, and the ethical restrictions in the Horizon Europe Regulation including Article 19, with recipients required to give undertakings and representations consistent with Luxembourg fund market practice.

The list itself is worth reading in full if there is any chance your value chain touches it:

• Harmful or exploitative forced labour, or harmful child labour
• Products or activities illegal under host country law or international conventions
• Pornography or prostitution
• Wildlife or wildlife products regulated under CITES
• Hazardous materials such as radioactive materials, unbounded asbestos fibres and products containing polychlorinated biphenyls
• Cross-border trade in waste unless compliant with the Basel Convention and underlying national and EU regulations, though using waste as fuel in district heating is not excluded
• Unsustainable fishing methods, meaning drift net fishing using nets over 2.5 km and blast fishing
• Pharmaceuticals, pesticides, herbicides, chemicals, ozone depleting substances and other hazardous substances subject to international phase-outs or bans
• Destruction of critical habitats
• Racist, anti-democratic or neo-Nazi media
• Tobacco, where it forms a substantial part of the business
• Live animals for scientific and experimental purposes, including breeding them
• Gambling, casinos, equivalent enterprises, or hotels hosting such facilities
• Commercial concessions over or logging in tropical natural forest, and conversion of natural forest into plantation
• Logging equipment for tropical natural or high nature value forests, and activities leading to clear cutting or degradation of such forests
• New palm oil plantations
• Any business with political or religious content
• Projects limiting individual rights and freedoms or violating human rights
• Activities referred to in Article 18 of the Horizon Europe Regulation on ethical principles
• Development of lethal autonomous weapons without the possibility of meaningful human control over selection and engagement decisions when carrying out strikes against humans

The final item carries the defence-related carve-out. The exclusion applies without prejudice to funding actions for the development of early warning systems and countermeasures for defensive purposes. Dual-use and defensive technology companies are therefore not categorically excluded, but the boundary is drawn at autonomous lethality without meaningful human control.

Note also the item on live animals for scientific and experimental purposes. Several life science business models sit closer to that line than their founders assume, and it is better checked at proposal stage than during due diligence.

What This Means in Practice

Reading the guidelines as an operating document rather than a legal one, a handful of consequences follow for anyone preparing an application or waiting on an investment decision.

• Prepare a due diligence pack before you are asked. The seven financial and commercial focus areas, the KYC extension to shareholders and ultimate beneficial owners, and the IP ownership question can all be answered in advance. Refusal or inability to provide requested information is itself a Bucket 0 ground.
• Reconcile your proposal figures with your books. A contradiction between the two is named explicitly as a disqualifier.
• Fix IP ownership before due diligence. IP that is not directly owned by or accessible to the applicant, or that is in litigation, is a stated ground for refusal.
• Screen your existing cap table. A single shareholder or beneficial owner in a non-eligible jurisdiction, or one falling under an exclusion, can stop the investment for the whole company.
• Model the matching requirement honestly. In Bucket 1 the second tranche requires private money matching the Fund's total exposure including the first-tranche convertible, not just the tranche still outstanding.
• Bring investors early. Bucket 2 and 3 treatment depends on demonstrable co-investor interest, and Bucket 2 allows the Fund to lean on the co-investor's own due diligence, which is the shortest path through the process.
• Do not confuse a staged tranche with a follow-on. Only amounts beyond the award decision are follow-ons, and those need an ex ante amending decision and available budget.
• Plan for a long holding period. Seven to ten years on average, up to fifteen in general, with exit generally alongside the lead investor and possibly earlier if EIC support is no longer needed.
• Put an ESOP in place. Founder and team incentives appear both as a Bucket 0 risk factor and as a named element of exit preparation.
• Keep value and IP in the EU. Both the general commitment and the safeguards regime point the same way, and offshoring plans will surface during negotiation.

The broader point is one of expectation setting. An EIC Accelerator funding recommendation is an authorisation to enter an investment process, not a payment instruction. For the empirical picture of how long that process actually takes and how much of the approved equity reaches company accounts, see the analysis of EIC Fund equity payment rates and investment delays and the full dataset in the EIC Accelerator and EIC Fund investment statistics. For the amounts and rates behind the two components, see EIC Accelerator funding explained.

Official reference: European Innovation Council and SMEs Executive Agency, Investment Guidelines for the Horizon Europe Compartment, published 27 August 2026. See the EIC Accelerator and EIC STEP Scaleup pages for the current programme documentation.